Business Segments — Other Nonoperating Income (Expense)
Pfizer Business Segments — Other Nonoperating Income (Expense) increased by 48.7% to $116.00M in Q1 2026 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase in net income from these items may indicate successful financial investments or favorable currency impacts, while an increase in net expense may signal rising debt costs or losses on non-core assets.
Detailed definition
This metric captures the net financial impact of activities outside the core pharmaceutical research, development, and c...
Peer comparison
Most large pharmaceutical companies report similar non-operating items, often categorized under 'Other Income/Expense' or 'Financial Items' in segment reporting, though the specific components can vary based on the company's treasury and investment strategy.
pfe_segment_biopharma_other_nonoperating_income_expenseHistorical Data
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $78.00M | $116.00M |
| QoQ Change | — | +48.7% |
| YoY Change | — | +48.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's business segments — other nonoperating income (expense)?
- Pfizer (PFE) reported business segments — other nonoperating income (expense) of $116.00M in Q1 2026.
- What does business segments — other nonoperating income (expense) mean?
- The net total of financial gains or losses that are not related to the core pharmaceutical business operations.